Skip to content
Psoriasis: The Missing Manual

References

  1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006. PubMed

  2. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis — current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164-191. doi:10.1007/s12016-024-08991-7. PMC

  3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6. Lancet

  4. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004. Full text

  5. Dand N, Mahil SK, Capon F, et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. Nat Commun. 2025;16:2051. doi:10.1038/s41467-025-56719-8. Nature

  6. Capon F. Psoriasis and genetics. Acta Derm Venereol. 2020;100(3):adv00030. Full text

  7. Bui A, Kumar S, Liu J, et al. A partitioned 88-loci psoriasis genetic risk score reveals HLA and non-HLA contributions to clinical phenotypes in a Newfoundland psoriasis cohort. Front Genet. 2023;14:1141010. Frontiers

  8. Strange A, Capon F, Spencer CCA, et al. Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985-990. PMC

  9. Patel HA, Revankar RR, Pedroza ST, Graham S, Feldman SR. Psoriasis gene expression and the role of those genes in treatment response. Int J Mol Sci. 2023;24(16):12564. PMC

  10. Ran D, Cai M, Zhang X. Genetics of psoriasis: a basis for precision medicine. Precis Clin Med. 2019;2(2):120-130. doi:10.1093/pcmedi/pbz011. Oxford Academic

  11. Xiong Y, Xue J, Tong M, Xu T, Bai X. Dynamic trend analysis of global psoriasis burden from 1990 to 2021. Front Public Health. 2025;13:1518681. PMC

  12. Dimmock PW, Aalemi AK, Parisi R, et al. Global epidemiology of psoriasis: Global Psoriasis Atlas 2024 update. Br J Dermatol. 2024;191(Suppl_3):ljae360.061. Oxford Academic

  13. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212. PubMed

  14. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. PubMed

  15. Dairov A, Issabekova A, Sekenova A, et al. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan. J Clin Med Kazakhstan. 2024;21(2):18-30. Full text (PDF)

  16. Zhu X, Zheng A, et al. Triggers for the onset and recurrence of psoriasis: a review and update. Cell Commun Signal. 2024;22:108. doi:10.1186/s12964-023-01381-0. Springer

  17. Ko SH, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;7:CD011972. PMC

  18. Naldi L. Psoriasis and smoking: links and risks. Psoriasis (Auckl). 2016;6:65-71. PMC

  19. Luca M, et al. The role of smoking in psoriasis. Medicina (Kaunas). 2024;60(5):856. PMC

  20. Zhou W, et al. Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in PASI after eight weeks of treatment. Tob Induc Dis. 2024;22:60. Full text

  21. Musumeci ML, et al. The role of lifestyle and nutrition in psoriasis: current status of knowledge and interventions. Dermatol Ther. 2022;35(9):e15685. PMC

  22. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39(3):212-218. doi:10.1111/j.1346-8138.2011.01408.x. PubMed

  23. Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211. MDPI

  24. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119-132. Dove Press

  25. Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021;77(13):1670-1680. JACC

  26. National Psoriasis Foundation. What are the related medical conditions of psoriasis? Updated 2024. Website

  27. ten Bergen LL, et al. The TNF/IL-23/IL-17 axis — head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946. Wiley

  28. Fatani M, et al. Review on recommendations on the use of biologic treatments for psoriasis. Expert Opin Biol Ther. 2025. Taylor & Francis (PDF)

  29. Sbidian E, Chaimani A, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7:CD011535. Cochrane

  30. Childs B, Romanelli S, Merola JF, Gottlieb AB. From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments. J Clin Aesthet Dermatol. 2025;18(2):16-22. PMC

  31. Drakos A, et al. Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. Pharmaceuticals (Basel). 2024;17(1):137. PMC

  32. Gopika M, et al. Advances in psoriasis research: from pathogenesis to therapeutics. Life Sci. 2024;355:122935. ScienceDirect

  33. Al-Kufi SNH, et al. Advancements in understanding and treating psoriasis: a comprehensive review. PeerJ. 2025;13:e19354. PMC

  34. Tsankov NK, et al. Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci. 2019;20(3):739. MDPI

  35. Armstrong AW, et al. Psoriasis. Nat Rev Dis Primers. 2025;11:46. Nature

  36. Wang X, et al. Global burden of psoriasis from 1990 to 2021 and potential factors: a systematic analysis. J Invest Dermatol. 2025 (in press). ScienceDirect

  37. Li X, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Int Immunopharmacol. 2019;62:46-58. ScienceDirect

  38. Fotiadou C, et al. New therapies in the biological treatment of psoriasis: a review. Biologics. 2025;5(2):19. MDPI

  39. Liu J, et al. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863-872. PubMed

  40. Lebwohl MG, et al. Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2025;15:1497-1527. PMC

  41. Chen H, et al. Systemic psoriasis: from molecular mechanisms to global management strategies. Clin Rev Allergy Immunol. 2025. doi:10.1007/s12016-025-09089-4. Springer

  42. Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179(1):16-29. doi:10.1111/bjd.16239. PubMed

  43. Li T, et al. A practical guide to biologic treatments for psoriasis in Asia. Asian Pac J Allergy Immunol. 2025 (online). Full text (PDF)

  44. Cheng Y, et al. GWAS and comprehensive analysis of psoriasis in the Taiwanese population. Mol Med Rep. 2024;30(1):104. Spandidos

  45. Egilman AC, Kesselheim AS, Avorn J, Raymakers AJN, Rome BN. Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis. JAMA Dermatol. 2024;160(4):409-416. doi:10.1001/jamadermatol.2023.6236. PMC

  46. Rome BN, Han J, Mooney H, Kesselheim AS. Use and cost of first-line biologic medications to treat plaque psoriasis in the US. JAMA Dermatol. 2025;161(6):622-628. doi:10.1001/jamadermatol.2025.0669. PubMed

  47. Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495-1502. doi:10.1111/bjd.15756. PubMed

  48. National Psoriasis Foundation. Current biologics on the market for psoriatic disease. Website

  49. Rome BN, Bhaskar A, Kesselheim AS. Use, Spending, and Prices of Adalimumab Following Biosimilar Competition. JAMA Health Forum. 2024;5(12):e243964. doi:10.1001/jamahealthforum.2024.3964. PubMed

  50. Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZN. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies. JAMA Dermatol. 2023;159(7):763-771. doi:10.1001/jamadermatol.2023.1338. PubMed

  51. Lewitt G, et al. Psoriasis therapies in 2024 and beyond. Dermatology Times. 2024. Website

  52. Brajac I, Gruber F. History of Psoriasis. In: O’Daly J, editor. Psoriasis — A Systemic Disease. Rijeka: IntechOpen; 2012. p. 57-68. doi:10.5772/27640. IntechOpen

  53. Holubar K. Psoriasis and parapsoriasis: since 200 and 100 years, respectively. J Eur Acad Dermatol Venereol. 2003;17(2):126-127. doi:10.1046/j.1468-3083.2003.00622.x. JEADV

  54. Willan R. On Cutaneous Diseases. Vol. 1. London: J. Johnson; 1808. Internet Archive

  55. Auspitz H. Ueber das Verhaltniss der Oberhaut zur Papillarschicht. Archiv fur Dermatologie und Syphilis. 1870;2:24-58. doi:10.1007/BF01822714. Springer

  56. Ingram JT. The approach to psoriasis. Br Med J. 1953;2(4836):591-594. doi:10.1136/bmj.2.4836.591. BMJ

  57. Dennis M, Bhutani T, Koo J, Liao W. The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. J Dermatolog Treat. 2013;24(4):319-327. PMC

  58. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm. 1958;78(2):200-203. doi:10.1001/archderm.1958.01560080060010. PubMed

  59. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555. doi:10.1056/NEJM197909063011016. PubMed

  60. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ. 1990;300(6729):908. doi:10.1136/bmj.300.6729.908. BMJ

  61. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895. doi:10.1001/archdermatol.2010.186. PubMed

  62. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. doi:10.1038/jid.2014.530. PubMed

  63. Williams K, Lada G, Reynolds NJ, et al. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from BADBIR. Clin Exp Dermatol. 2025;50(4):804-811. doi:10.1093/ced/llae449. PubMed

  64. Griffiths CEM, Fava M, Miller AH, et al. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis. Psychother Psychosom. 2017;86(5):260-267. doi:10.1159/000479163. PubMed

  65. Abboud E, Chrayteh D, Boussetta N, et al. Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment. Nat Commun. 2024;15(1):6718. doi:10.1038/s41467-024-50993-8. PMC

  66. Olafsson S, Rodriguez E, Lawson ARJ, et al. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin. Nat Genet. 2023;55(11):1892-1900. doi:10.1038/s41588-023-01545-1. PubMed

  67. Bissonnette R, Soung J, Hebert AA, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med. 2025;393(18):1784-1795. doi:10.1056/NEJMoa2504187. PubMed

  68. Armstrong AW, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024. PubMed

  69. Nielsen ML, Thein D, Rasmussen MK, et al. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study. J Am Acad Dermatol. 2023;88(6):1378-1381. doi:10.1016/j.jaad.2023.01.029. PubMed

  70. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141(5):601-606. doi:10.1001/archderm.141.5.601. PubMed

  71. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233. doi:10.1136/annrheumdis-2017-212196. PubMed

  72. Jeong YD, Jo H, Cho H, et al. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes: Findings from WHO Pharmacovigilance Study. Int Arch Allergy Immunol. 2025;186(6):579-593. doi:10.1159/000542217. PubMed

  73. National Institute for Health and Care Excellence. Psoriasis: assessment and management (CG153). Updated September 2017. NICE

  74. Meeuwis KAP, de Hullu JA, van de Nieuwenhof HP, Evers AWM, Massuger LFAG, van de Kerkhof PCM, van Rossum MM. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164(6):1247-1255. doi:10.1111/j.1365-2133.2011.10249.x. PubMed

  75. Mahil SK, Dand N, Mason KJ, et al.; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis — insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71. doi:10.1016/j.jaci.2020.10.007. PubMed

  76. Yiu ZZN, Ashcroft DM, Evans I, et al.; BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from BADBIR. Br J Dermatol. 2019;180(2):329-337. doi:10.1111/bjd.17036. PubMed

  77. MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4(7):e490-e506. doi:10.1016/S2665-9913(22)00098-4. PubMed

  78. Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2022;4(1):e42-e52. doi:10.1016/S2665-9913(21)00333-7. PubMed

  79. Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339-1344. doi:10.1136/annrheumdis-2021-220597. PubMed

  80. Haberman RH, Um S, Engel AJ, et al.; SAGA investigators. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol. 2022;4(6):e384-e387. doi:10.1016/S2665-9913(22)00069-8. PubMed

  81. Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 — Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021;84(5):1254-1268. doi:10.1016/j.jaad.2020.12.058. PubMed

  82. Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, et al. Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. JAMA Dermatol. 2025;161(12):1215-1223. doi:10.1001/jamadermatol.2025.3410. PubMed

  83. Bittiner SB, Tucker WF, Cartwright I, Bleehen SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet. 1988;1(8582):378-380. doi:10.1016/S0140-6736(88)91181-6. PubMed

  84. Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med. 1993;328(25):1812-1816. doi:10.1056/NEJM199306243282504. PubMed

  85. Huang YW, Tsai TF. Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience. Dermatol Ther (Heidelb). 2019;9(3):553-569. doi:10.1007/s13555-019-0310-5. PubMed

  86. Armstrong AW, Gondo GC, Merola JF, et al.; Remission Workgroup of the National Psoriasis Foundation. Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. JAMA Dermatol. 2025;161(8):863-869. doi:10.1001/jamadermatol.2025.1625. PubMed

  87. Ibrahim GH, Buch MH, Lawson C, Rajber R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469-474. PubMed

  88. Chen H, Poon A, Yeung C, et al. A Genetic Risk Score Combining Ten Psoriasis Risk Loci Improves Disease Prediction. PLoS ONE. 2011;6(4):e19454. doi:10.1371/journal.pone.0019454. PLOS ONE

  89. Kolchak NA, Tetarnikova MK, Theodoropoulou MS, Michalopoulou AP, Theodoropoulos DS. Prevalence of antigliadin IgA antibodies in psoriasis vulgaris and response of seropositive patients to a gluten-free diet. J Multidiscip Healthc. 2018;11:13-19. doi:10.2147/JMDH.S122256. PubMed

  90. Jensen P, Zachariae C, Christensen R, et al. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study. Am J Clin Nutr. 2016;104(2):259-265. doi:10.3945/ajcn.115.125849. PubMed

  91. Mackensen A, Muller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124-2132. doi:10.1038/s41591-022-02017-5. PubMed

  92. Muller F, Boeltz S, Knitza J, Schett G, et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N Engl J Med. 2024;390(8):687-700. doi:10.1056/NEJMoa2308917. PubMed

  93. Wang SY, An WH, Wang ZS, et al. Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report. Front Immunol. 2024;15:1418768. doi:10.3389/fimmu.2024.1418768. PubMed

  94. Yi JZ, McGee JS. Epigenetic-modifying therapies: an emerging avenue for the treatment of inflammatory skin diseases. Exp Dermatol. 2021;30(8):1167-1176. doi:10.1111/exd.14334. PubMed

  95. Nadeem A, Al-Harbi NO, Al-Harbi MM, et al. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. Pharmacol Res. 2015;99:248-257. doi:10.1016/j.phrs.2015.06.001. PubMed

  96. Huang K, Wu X, Li Y, et al. Artificial intelligence-based psoriasis severity assessment: real-world study and application. J Med Internet Res. 2023;25:e44932. doi:10.2196/44932. PubMed

  97. Goessinger EV, Gottfrois P, Mueller AM, Cerminara SE, Navarini AA. Image-based artificial intelligence in psoriasis assessment: the beginning of a new diagnostic era? Am J Clin Dermatol. 2024;25(6):861-872. doi:10.1007/s40257-024-00883-y. PubMed

  98. Zhang X, He Y. The role of nociceptive neurons in the pathogenesis of psoriasis. Front Immunol. 2020;11:1984. doi:10.3389/fimmu.2020.01984. PubMed

  99. Sayed BA, et al. Apremilast: First Pediatric Approval. Paediatr Drugs. 2024. doi:10.1007/s40272-024-00659-x. PubMed

  100. Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. In: Bhutani T, Liao W, Nakamura M, editors. Evidence-Based Psoriasis. Springer; 2018. p. 1-16. PMC

  101. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542-1551. doi:10.1038/jid.2013.508. PubMed

  102. National Psoriasis Foundation. Psoriasis Health Indicator Report. 2024. Website

  103. Adelekun A, Onyekaba G, Lipoff JB. Skin color in dermatology textbooks: An updated evaluation and analysis. J Am Acad Dermatol. 2021;84(1):194-196. doi:10.1016/j.jaad.2020.04.084. PubMed

  104. Queiro R, Morante I, Cabezas I, Acasuso B. HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford). 2016;55(2):221-229. doi:10.1093/rheumatology/kev296. PubMed

  105. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007-1011. doi:10.1111/j.1468-3083.2011.04065.x. PubMed

  106. Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2025;192(5):826-836. doi:10.1093/bjd/ljae402. PubMed

  107. Armstrong AW, Soliman AM, Betts KA, et al. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatol Ther (Heidelb). 2021;11(3):885-905. doi:10.1007/s13555-021-00511-1. PubMed

  108. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057. PubMed

  109. Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749-759. doi:10.1093/bjd/ljad035. PubMed

  110. Lin YK, Wong WR, Chang YC, et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology. 2007;214(2):155-161. doi:10.1159/000098576. PubMed

  111. Lv M, Deng J, Tang N, Zeng Y, Lu C. Efficacy and safety of Tripterygium wilfordii Hook F on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2018;2018:2623085. doi:10.1155/2018/2623085. PubMed

  112. Yeh ML, Ko SH, Wang MH, Chi CC, Chung YC. Acupuncture-related techniques for psoriasis: a systematic review with pairwise and network meta-analyses of randomized controlled trials. J Altern Complement Med. 2017;23(12):930-940. doi:10.1089/acm.2016.0158. PubMed

  113. Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;84(5):565-578. doi:10.1007/s40265-024-02028-1. PubMed

  114. Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514-521. doi:10.1111/ced.12841. PubMed

  115. Molina-Leyva A, Jimenez-Moleon JJ, Naranjo-Sintes R, Ruiz-Carrascosa JC. Sexual dysfunction in psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(4):649-655. doi:10.1111/jdv.12845. PubMed

  116. Taylor W, Gladman D, Helliwell P, et al.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. doi:10.1002/art.21972. PubMed

  117. Dai Q, Zhang Y, Liu Q, Zhang C. Efficacy and safety of vitamin D supplementation on psoriasis: a systematic review and meta-analysis. PLoS One. 2023;18(11):e0294239. doi:10.1371/journal.pone.0294239. PubMed

  118. Morrow A, et al. The effect of weight-loss interventions on psoriasis severity and metabolic outcomes: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2025;39(7):1636-1648. doi:10.1111/jdv.20415. PubMed

  119. Anheyer D, et al. Herbal medicines for psoriasis: a systematic review. Complement Ther Med. 2025;89:103134. ScienceDirect

  120. Wang Q, Wang J, Sun X, et al. Evidence-based dietary recommendations for patients with psoriasis: a systematic review. Clin Nutr. 2025;47:68-82. doi:10.1016/j.clnu.2025.02.005. ScienceDirect

  121. Michaëlsson G, Gerdén B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol. 2000;142(1):44-51. doi:10.1046/j.1365-2133.2000.03240.x. PubMed

  122. Balak DMW, et al. Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation. J Am Acad Dermatol. 2022;87(3):551-559. PubMed

  123. Zhou T, Koussiouris J, Kim L, Vender R. Management of guttate psoriasis: a systematic review. Front Cell Dev Biol. 2024;12:1473276. PMC

  124. Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol. 2010;37(10):894-899. doi:10.1111/j.1346-8138.2010.00871.x. PubMed

  125. Galili E, Rubinstein Levy S, Golan-Tripto I, et al. New-onset guttate psoriasis: a long-term follow-up study. Dermatology. 2023;239(2):233-239. doi:10.1159/000528395. PMC

  126. Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37(5):1004-1016. doi:10.1111/jdv.18846. JEADV

  127. Eyerich K, et al. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024;160(9):953-963. doi:10.1001/jamadermatol.2024.2463. PubMed

  128. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130-141. doi:10.1056/NEJMoa2102388. NEJM

  129. Floris A, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology. 2025;64(3):1131-1137. Oxford Academic

  130. Lada G, Chinoy H, Heal C, Warren RB, Talbot PS, Kleyn CE. Depression and suicidality in patients with psoriasis and the role of psoriatic arthritis: a cross-sectional study in a tertiary setting. J Acad Consult Liaison Psychiatry. 2022;63(4):372-383. doi:10.1016/j.jaclp.2021.12.007. PubMed

  131. Balato N, Patruno C, Napolitano M, Patri A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233-238. doi:10.1007/s40266-014-0156-6. PubMed

  132. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961-969. doi:10.1001/jamadermatol.2015.0718. PubMed

  133. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf. 2015;38(5):493-509. doi:10.1007/s40264-015-0287-7. PubMed

  134. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087. PubMed

  135. Kleyn CE, Morsman E, Griffin L, et al. Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. J Dermatolog Treat. 2019;30(4):311-319. doi:10.1080/09546634.2019.1620502. Taylor & Francis

  136. Tremezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: where are we standing and where will we be going? Dermato-Endocrinology. 2011;3(3):180-186. doi:10.4161/derm.3.3.17534. PMC

  137. Zhao Y, Asahina A, Asawanonda P, et al. Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis. J Dermatol. 2021;48(7):940-960. doi:10.1111/1346-8138.15806. PubMed

  138. Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis (Auckl). 2016;6:153-163. doi:10.2147/PTT.S101233. PMC

  139. Amiri D, Schwarz CW, Gether L, et al. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol. 2023;103:adv6525. doi:10.2340/actadv.v103.6525. PMC

  140. Sekhon S, Jeon C, Nakamura M, et al. Review of the mechanism of action of coal tar in psoriasis. J Dermatolog Treat. 2018;29(3):230-232. doi:10.1080/09546634.2017.1369494. PubMed

  141. Avalos-Viveros M, Esquivel-Garcia R, Garcia-Perez M, et al. Updated view of tars for psoriasis: what have we learned over the last decade? Int J Dermatol. 2023;62(3):290-301. doi:10.1111/ijd.16193. Wiley

  142. Statham BN, Ryatt KS, Rowell NR. Short-contact dithranol therapy — a comparison with the Ingram regime. Br J Dermatol. 1984;110(6):703-708. doi:10.1111/j.1365-2133.1984.tb04708.x. PubMed

  143. Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther (Heidelb). 2015;5(1):1-18. doi:10.1007/s13555-015-0068-3. PMC

  144. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37(1):85-92. doi:10.1016/S0190-9622(97)70216-0. ScienceDirect

  145. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. doi:10.1056/NEJMoa2103629. PubMed

  146. Contento M, Cline A, Russo M. Steroid phobia: a review of prevalence, risk factors, and interventions. Am J Clin Dermatol. 2021;22(6):837-851. doi:10.1007/s40257-021-00623-6. PubMed

  147. Long CC, Finlay AY. The finger-tip unit — a new practical measure. Clin Exp Dermatol. 1991;16(6):444-447. doi:10.1111/j.1365-2230.1991.tb01232.x. PubMed

  148. U.S. Food and Drug Administration. ZORYVE (roflumilast) cream prescribing information. Silver Spring, MD: FDA; 2022. FDA Label

  149. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479. doi:10.1038/s41584-022-00798-0. PubMed

  150. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050. doi:10.1136/annrheumdis-2013-204858. PubMed

  151. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273-2284. doi:10.1016/S0140-6736(18)30830-4. PubMed

  152. Bhatia BK, Millsop JW, Debbaneh M, et al. Diet and psoriasis, part 2: celiac disease and role of a gluten-free diet. J Am Acad Dermatol. 2014;71(2):350-358. doi:10.1016/j.jaad.2014.03.017. PMC

  153. Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120-2130. doi:10.1016/j.jaci.2018.11.038. Full text

  154. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x. PubMed

  155. Boyd AS, Neldner KH. The isomorphic response of Koebner. Int J Dermatol. 1990;29(6):401-410. doi:10.1111/j.1365-4362.1990.tb03821.x. PubMed

  156. World Health Organization. Global Report on Psoriasis. Geneva: World Health Organization; 2016. WHO

  157. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142-152. doi:10.1056/NEJMoa2102383. NEJM

  158. U.S. Food and Drug Administration. ZORYVE (roflumilast) cream 0.3% and 0.15% prescribing information (supplement approval for ages 6+). Silver Spring, MD: FDA; 2023. FDA Label

  159. U.S. Food and Drug Administration. ZORYVE (roflumilast) topical foam, 0.3% prescribing information. Silver Spring, MD: FDA; 2025. FDA Label

  160. Shou Y, Yang L, Yang Y, Xu J. Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death Dis. 2024;15(11):831. doi:10.1038/s41419-024-07219-8. PubMed

  161. Naik S, Fuchs E. Inflammatory memory and tissue adaptation in sickness and in health. Nature. 2022;607:249-255. doi:10.1038/s41586-022-04919-3. Nature

  162. Wadhavane S, Rithvik A, Rasool M. Psoriasis relapse: exploring the role of epigenetics, metabolic reprogramming, and inflammatory memory. Immunol Invest. 2025;54(7):2519666. doi:10.1080/08820139.2025.2519666. Taylor & Francis

  163. Akiyama M. Updated genetic background of generalized pustular psoriasis as an autoinflammatory keratinization disease. J Dermatol. 2025;52(3):400-407. doi:10.1111/1346-8138.17585. Wiley

  164. Krueger JG, Sarkar MK, Lebwohl MG, et al. Spesolimab mitigates residual inflammation and prevents flares in generalised pustular psoriasis. J Clin Invest. 2025;135(17):e188530. doi:10.1172/JCI188530. JCI

  165. Mahil SK, Twelves S, Mostowy S, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136(11):2064-2073. doi:10.1016/j.jid.2016.06.616. PubMed

  166. Zhang Y, Wang C, Li L, et al. IL-17A impairs autophagy in psoriatic keratinocytes via mTOR pathway activation. Front Immunol. 2025;16:1489235. PMC

  167. Jiang M, Fang H, Shao S, et al. Extracellular vesicles in psoriasis pathogenesis: from biomarkers to therapeutic targets. Front Immunol. 2024;15:1360618. doi:10.3389/fimmu.2024.1360618. Frontiers

  168. Tang B, et al. The role of extracellular vesicles in the development and treatment of psoriasis: narrative review. Int J Mol Sci. 2024;25(24):13677. PMC

  169. Kamleh MA, Snowden SG, Grapov D, et al. LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment. J Proteome Res. 2015;14(1):557-566. doi:10.1021/pr500782g. ACS

  170. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32-38. PubMed

  171. Balak DMW, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017;7:87-94. doi:10.2147/PTT.S126727. PMC

  172. Nam KH, et al. Emerging therapies for palmoplantar pustulosis with a focus on IL-23 inhibitors. J Clin Med. 2025;14(10):3273. doi:10.3390/jcm14103273. MDPI

  173. Terui T, et al. Apremilast for palmoplantar pustulosis: a Phase 3 trial in Japan. J Eur Acad Dermatol Venereol. 2024. doi:10.1111/jdv.70166. Wiley

  174. Sorokin AV, Patel N, Engel LC, et al. Plasma proteomics-based risk scoring for psoriasis diagnosis. J Invest Dermatol. 2025;145(7):1589-1598. PMC

  175. Zhang PW, Dong Q, Wang H, et al. Identification of plasma metabolites and dipeptides as diagnostic biomarkers for psoriasis vulgaris through LC-HRMS-based metabolomics. J Proteome Res. 2025;24(1):46-54. doi:10.1021/acs.jproteome.4c00173. ACS

  176. Mateescu LA, et al. The intersection of psoriasis and neoplasia: risk factors, therapeutic approaches, and management strategies. Cancers. 2024;16(24):4224. doi:10.3390/cancers16244224. MDPI

  177. Li R, Luo W, Chen X, et al. An observational and genetic investigation into the association between psoriasis and risk of malignancy. Nat Commun. 2024;15:7952. doi:10.1038/s41467-024-51824-6. Nature

  178. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. Front Med. 2023;10:1175477. doi:10.3389/fmed.2023.1175477. Frontiers

  179. Almutairi AG, et al. Ocular manifestations of psoriasis: a systematic review. Ocul Immunol Inflamm. 2025;33(5). doi:10.1080/09273948.2025.2459710. Taylor & Francis

  180. Kubovsky S, et al. Biologic therapy is associated with reduced ocular disease in psoriasis: a real-world study. Eye. 2026. doi:10.1038/s41433-026-04274-x. Nature Eye

  181. Ger TY, Lien KH, Chi CC. Association of psoriasis with hearing loss: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(6):625-633. doi:10.1001/jamadermatol.2023.0830. PubMed

  182. Keller JJ, Lin HC. The association between psoriasis and periodontal disease: a systematic review and meta-analysis. J Clin Periodontol. 2022;49(Suppl 24):S115-S128. PMC

  183. Marruganti C, Pacifici A, Gatto R, et al. Treatment of periodontitis ameliorates the severity and extent of psoriasis: a randomized clinical trial. J Clin Periodontol. 2025;52(1):53-63. doi:10.1111/jcpe.14040. PubMed

  184. Passos JSG, Villani AC, Machado PRL, et al. Osteoporosis and bone health in psoriasis: a narrative review. J Clin Med. 2022;11(19):5800. PMC

  185. Nowowiejska J, et al. Psoriasis and neurodegenerative diseases — a review. Front Mol Neurosci. 2022;15:917751. doi:10.3389/fnmol.2022.917751. Frontiers

  186. Supajarupan T, et al. The prevalence of high risk of obstructive sleep apnea in patients with psoriasis. Sleep Breath. 2025;29(1):148. PMC

  187. Smith P, Jin JQ, Spencer RK, et al. Psoriasis and sleep disturbance: a US population-based study using the NHANES database. Dermatol Ther (Heidelb). 2024;14(8):2277-2283. doi:10.1007/s13555-024-01211-2. Springer

  188. Zhang Y, Li P, Chen S, et al. Sexual dysfunction in psoriasis: a systematic review and meta-analysis. Front Public Health. 2024;12:1339196. doi:10.3389/fpubh.2024.1339196. Frontiers

  189. Yüksek T, et al. Impact of adalimumab on erectile dysfunction, sperm parameters and hormonal profile in male psoriasis patients. Arch Dermatol Res. 2024;316(8):512. doi:10.1007/s00403-024-03520-0. Springer

  190. Jaworecka K, Rzepko M, Murer C, et al. The neuro-immune itch axis in psoriasis: TRPV1, IL-31, and NGF pathways. Inflammation. 2025;48(2):567-582. doi:10.1007/s10753-025-02385-3. Springer

  191. Takahashi K, Yamasaki K. Skin microbiota, NGF, and TRPV1: a neuro-microbial axis in psoriatic itch. Int Immunopharmacol. 2023;124:110934. doi:10.1016/j.intimp.2023.110934. ScienceDirect

  192. Akdeniz M, Ünal S, Yücel A, et al. Central sensitisation and neuropathic pain in psoriatic arthritis. Rheumatol Int. 2025;45(5):789-798. PMC

  193. Doneddu PE, et al. Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis: a prospective cohort study. Muscle Nerve. 2024;70(4):567-574. doi:10.1002/mus.28196. Wiley

  194. Pelet del Toro N, Yahia R, Feldman SR, et al. National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine. JAAD Int. 2023;12:98-112. doi:10.1016/j.jdin.2023.04.002. PMC

  195. Smith CH, Yiu ZZN, Bale T, et al. Digital health and remote monitoring in psoriasis. Front Digit Health. 2025;7:1656585. doi:10.3389/fdgth.2025.1656585. Frontiers

  196. Zhu Y, Wang H, Li C, et al. The gut-skin axis in psoriasis: microbiome-immune interactions. Front Microbiol. 2025;16:1711288. doi:10.3389/fmicb.2025.1711288. Frontiers

  197. Jimenez-Sanchez M, et al. The gut-skin axis: a bi-directional, microbiota-driven relationship with therapeutic potential. Gut Microbes. 2025;17(1):2473524. doi:10.1080/19490976.2025.2473524. Taylor & Francis

  198. Koike Y, Kuwatsuka S, Motooka D, Murota H. Dysbiosis of the human skin mycobiome in patients receiving systemic IL-23 inhibitors. Allergol Int. 2025;74(1):72-77. doi:10.1016/j.alit.2024.06.003. PubMed

  199. Chen L, Huang X, Zhao J, et al. Association between ambient air pollution and psoriasis: a systematic review and meta-analysis. Environ Sci Pollut Res. 2024;31(38):50789-50802. PubMed

  200. Leng RX, Zhang J, Du CJ, et al. Unraveling the link between air pollution and psoriasis subtypes: genetic architecture of epigenetic insights and mediating cytokines. Environ Sci Technol. 2025;59(30):15637-15648. doi:10.1021/acs.est.5c01573. PubMed

  201. Bożek A, Reich A. The reliability of three psoriasis assessment tools: Psoriasis Area and Severity Index, body surface area and Physician Global Assessment. Adv Clin Exp Med. 2017;26(5):851-856. PMC

  202. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457-465. PMC

  203. Sheppard R, Gan L, Onambele-Pearson G, Young H. Increased physical activity promotes skin clearance, improves cardiovascular and psychological health, and increases functional capacity in patients with psoriasis. Skin Health Dis. 2024;4(5):e426. doi:10.1002/ski2.426. Wiley

  204. Zhu H, Sun P, Choi J, et al. Association of psoriasis disease with physical activity and exercise: systematic review and meta-analysis. BMC Sports Sci Med Rehabil. 2024;16:238. PMC

  205. Egilman AC, Wallach JD, Ross JS, et al. Prices of psoriasis biologics versus clinical benefit: an efficiency frontier analysis. JAMA Dermatol. 2024;160(3):301-309. doi:10.1001/jamadermatol.2023.5849. JAMA

  206. Saleem M, Akhtar N, Hussain A, et al. Nanomedicine for psoriasis: recent advances in drug delivery systems. Pharmaceutics. 2024;16(4):449. doi:10.3390/pharmaceutics16040449. MDPI

  207. Xu G, Ma G, Sun J, et al. Comprehensive analysis of pyroptosis-related genes in psoriasis and targeted gene editing of CASP1 and CASP5 using lipid nanoparticles to alleviate skin inflammation. Front Bioeng Biotechnol. 2025;13:1639869. doi:10.3389/fbioe.2025.1639869. Frontiers

  208. Lwin SM, et al. Mesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series. Front Immunol. 2025;16:1656724. doi:10.3389/fimmu.2025.1656724. Frontiers

  209. Kuang YH, et al. Expert consensus on the application of stem cells in psoriasis research and clinical trials. Aging Dis. 2025. doi:10.14336/AD.2024.0012. Aging and Disease

  210. Gelfand JM, Armstrong AW, Garg A, et al. National Psoriasis Foundation consensus statements on vaccination for psoriasis patients. J Am Acad Dermatol. 2024;91(5):978-989. PMC

  211. Sontam T, Cho SW, Chen A, Chen H, Raman J, Tarbox M. Psoriasis is associated with an increased risk of chronic kidney disease in diabetic patients despite renoprotective or biologic therapy: a retrospective cohort study. J Am Acad Dermatol. 2025;93(3):788-789. doi:10.1016/j.jaad.2025.03.098. JAAD

  212. He J, Zhang X, Ge Z, Shi J, Guo S, Chen J. Whole-body cryotherapy can reduce the inflammatory response in humans: a meta-analysis based on 11 randomized controlled trials. Sci Rep. 2025;15(1):7759. doi:10.1038/s41598-025-90396-3. Nature

  213. Natarelli N, Gahoonia N, Sivamani RK. Bacteriophages and the microbiome in dermatology: the role of the phageome and a potential therapeutic strategy. Int J Mol Sci. 2023;24(3):2695. doi:10.3390/ijms24032695. PMC

  214. Manchanda Y, De A, Das S, Chakraborty D. Disease assessment in psoriasis. Indian J Dermatol. 2023;68(3):278-281. doi:10.4103/ijd.ijd_420_23. PMC

  215. Kumar R, Mahajan M, Mahajan BB. Cryotherapy in chronic plaque psoriasis: an effective therapeutic modality. Egypt J Dermatol Venerol. 2024;44(2):73-79. doi:10.4103/ejdv.ejdv_38_23. LWW

  216. Phan C, Touvier M, Kesse-Guyot E, et al. Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Santé cohort. JAMA Dermatol. 2018;154(9):1017-1024. doi:10.1001/jamadermatol.2018.2127. PubMed

  217. Choonhakarn C, Busaracome P, Sripanidkulchai B, Sarakarn P. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2010;24(2):168-172. doi:10.1111/j.1468-3083.2009.03377.x. PubMed

  218. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940-946. doi:10.1001/jamadermatol.2021.2007. PubMed

  219. Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135(12):2955-2963. doi:10.1038/jid.2015.296. PubMed

  220. Takeshita J, Augustin M, de Jong EMGJ, et al. Health-related QOL differs by race/ethnicity in North American patients with psoriasis: results from PSOLAR. J Invest Dermatol. 2022;142(12):2528-2531.e3. doi:10.1016/j.jid.2022.02.013. PubMed

  221. Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1-8. doi:10.1016/j.coi.2017.07.007. PubMed

  222. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27. doi:10.1016/j.jaad.2005.07.073. PubMed

  223. Edwards F, de Berker D. Nail psoriasis: clinical presentation and best practice recommendations. Drugs. 2009;69(17):2351-2361. doi:10.2165/11318180-000000000-00000. PubMed

  224. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123-129. PubMed

  225. Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228-240. doi:10.1016/j.jaad.2019.01.072. PubMed

  226. de Vries ACQ, Bogaards NA, Hooft L, et al. Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013;(1):CD007633. doi:10.1002/14651858.CD007633.pub2. PubMed

  227. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954-966. doi:10.1111/bjd.17351. PubMed

  228. (duplicate of ref 108, removed)

  229. Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632-2640. doi:10.1038/jid.2015.208. PubMed

  230. Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294-302. doi:10.1111/bjd.18981. PubMed

  231. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148-1158. doi:10.1111/jdv.13611. PubMed

  232. (duplicate of ref 149, removed)

  233. Popa LG, Giurcaneanu C, Portelli MG, et al. Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice. Medicina (Kaunas). 2024;60(3):373. doi:10.3390/medicina60030373. PMC

  234. Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425-436. doi:10.1111/bjd.19262. PubMed

  235. Wu M, Fischer G. Adult genital psoriasis: An updated review for clinicians. Australas J Dermatol. 2024;65(3):e1-e12. doi:10.1111/ajd.14227. PubMed

  236. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586-592. doi:10.1111/j.1365-2133.2010.09941.x. PubMed

  237. World Health Organization. Global report on psoriasis. Geneva: WHO; 2016. WHO

  238. Charrow A, Xia FD, Joyce C, Mostaghimi A. Diversity in dermatology clinical trials: a systematic review. JAMA Dermatol. 2017;153(2):193-198. doi:10.1001/jamadermatol.2016.4129. PubMed

  239. Swanbeck G, Inerot A, Martinsson T, et al. A population-based study of the genetics of psoriasis. Br J Dermatol. 1994;131(1):32-39. doi:10.1111/j.1365-2133.1994.tb08454.x. PubMed

  240. Bobotsis R, Gulliver WP, Engasser H, Guenther L, Gulliver WP. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016;174(2):292-299. doi:10.1111/bjd.14241. PubMed

  241. Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20-31. doi:10.1111/bjd.12039. PubMed

  242. Ahn CS, Culp L, Engasser HCS, Kimball AB, Feldman SR. Adherence in dermatology. J Dermatolog Treat. 2017;28(2):94-103. doi:10.1080/09546634.2016.1181256. PubMed

  243. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9-14. doi:10.1111/j.1468-3083.2011.04060.x. PubMed

  244. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824. Erythrodermic psoriasis management reviewed in: Lebwohl M, Holliday A, Engasser HCS. Psoriasis: Treatment of erythrodermic psoriasis. In: UpToDate. 2022. PubMed

  245. Mossner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J Invest Dermatol. 2015;135(10):2538-2541. doi:10.1038/jid.2015.186. PubMed

  246. Brunasso AMG, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013;168(6):1243-1251. doi:10.1111/bjd.12223. PubMed

  247. Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol. 2013;14(2):87-109. doi:10.1007/s40257-013-0015-y. PubMed

  248. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer. 1994;73(11):2759-2764. doi:10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C. PubMed

  249. Bhutani T, Liao W, Engasser HCS, et al. Home phototherapy for psoriasis. J Am Acad Dermatol. 2020;83(3):855-862. doi:10.1016/j.jaad.2020.05.049. PubMed

  250. Warren RB, Blauvelt A, Engasser HCS, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase 3, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50-59. doi:10.1111/bjd.19341. PubMed

  251. Papadimitriou JC, Kousvelari A, Baer AN. Biologic therapy for psoriasis in solid organ transplant recipients: a systematic review. J Am Acad Dermatol. 2023;89(2):395-397. doi:10.1016/j.jaad.2023.03.027. PubMed

  252. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156(6):1245-1250. doi:10.1111/j.1365-2133.2007.07881.x. PubMed

  253. Basra MKA, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156(3):528-538. doi:10.1111/j.1365-2133.2006.07617.x. PubMed

  254. Grand View Research. Psoriasis drugs market size, share & trends analysis report. 2025. Grand View Research

  255. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651-658. doi:10.1001/jamadermatol.2014.3593. PubMed

  256. Nast A, Mrowietz U, Kragballe K, et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis — a multinational cross-sectional study. Arch Dermatol Res. 2015;307(5):391-399. doi:10.1007/s00403-015-1557-7. PubMed

  257. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166. PubMed

  258. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286. doi:10.1093/biostatistics/kxx069. PubMed

  259. Langley RG, Papp KA, Gott lieb AB, et al. Safety results from a pooled analysis of randomized, controlled trials of briakinumab in the treatment of moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27(10):1252-1262. doi:10.1111/j.1468-3083.2012.04705.x. PubMed

  260. Biosimilars Review & Report. 18 months of US adalimumab biosimilar competition yields $11 billion in savings. August 2024. Biosimilars R&R

  261. JMIR Dermatology. Cross-sectional analysis of psoriasis funding relative to disease burden. JMIR Dermatol. 2026;9(1):e71468. JMIR

  262. Xu H, Yin N. The effect of metformin on psoriasis: a meta-analysis of randomized controlled trials. Front Med (Lausanne). 2023;10:1276490. doi:10.3389/fmed.2023.1276490. PMC

  263. Hafez VG, Bosseila M, Halim MA, et al. Clinical effects of pioglitazone, an insulin-sensitizing drug, on psoriasis vulgaris and its comorbidities: a double-blinded randomized controlled trial. J Dermatolog Treat. 2019;30(7):681-686. doi:10.1080/09546634.2019.1573308. PubMed

  264. Medic G, Skundric K, Grbovic V, et al. Effect of semaglutide on psoriasis severity and metabolic parameters in obese patients with type 2 diabetes: an open-label randomized controlled trial. Eur Rev Med Pharmacol Sci. 2025;29(3):e39858442. PubMed

  265. Faurschou A, Knop FK, Thyssen JP, et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014;51(1):147-150. doi:10.1007/s00592-013-0504-6. PubMed

  266. Chua SHH, Tey HL, Lim DTH. Statin use is associated with improvement in psoriasis severity: a meta-analysis of randomized controlled trials. Dermatol Ther. 2020;33(2):e13224. doi:10.1111/dth.13224. PubMed

  267. Thorslund K, Svensson T, Nordlind K, et al. Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study. J Intern Med. 2013;274(3):281-287. doi:10.1111/joim.12093. PubMed